key: cord-0739316-dokvggbw authors: Bao, Mei; Yang, Sen; Gale, Robert Peter; Zhang, Yanli; Liu, Xiaoli; Zhu, Huanling; Liang, Rong; Liu, Bingcheng; Zhou, Li; Li, Zongru; Dou, Xuelin; Shi, Dayu; Wang, Tao; Meng, Li; Li, Weiming; Jiang, Qian title: Mental Health in Persons With Chronic Myeloid Leukemia During the SARS-CoV-2 Pandemic: The Need for Increased Access to Health Care Services date: 2021-06-08 journal: Front Psychiatry DOI: 10.3389/fpsyt.2021.679932 sha: 815f2fda58535207d0af72944bdf78f8bf62f3fe doc_id: 739316 cord_uid: dokvggbw Mental health problems in the general population have been reported during the SARS-CoV-2 pandemic; however, there were rare data in persons with chronic myeloid leukemia (CML). Therefore, we performed a cross-sectional study on mental health evaluated using the 9-item Patient Health Questionnaire (PHQ-9; depression), the 7-item Generalized Anxiety Disorder (GAD-7; anxiety), and the 22-item Impact of Event Scale—Revised (IES-R; distress), including subscales of avoidance, intrusion, and hyper-arousal in persons with CML, non-cancer persons, and immediate family members of persons with cancer as controls (≥16 years) by an online survey. Data from 3,197 persons with CML and 7,256 controls were collected. In multivariate analyses, CML was significantly associated with moderate to severe depression (OR = 1.6; 95% Confidence Interval [CI], 1.4, 1.9; p < 0.001), anxiety (OR = 1.4 [1.1, 1.7]; p = 0.001), distress (OR = 1.3 [1.1, 1.5]; p < 0.001), and hyper-arousal (OR = 1.5 [1.3, 1.6]; p < 0.001). Moreover, delay in regular monitoring was significantly associated with depression (OR 1.3 [1.0, 1.7]; p = 0.024), anxiety (OR = 1.3 [1.0, 1.8]; p = 0.044), avoidance (OR = 1.2 [1.0, 1.4]; p = 0.017), and intrusion (OR = 1.2 [1.0, 1.4]; p = 0.057); tyrosine kinase-inhibitor dose reduction or discontinuation, depression (OR = 1.9 [1.3, 2.8]; p = 0.001), distress (OR = 2.0 [1.4, 2.8]; p < 0.001), avoidance (OR = 1.6 [1.2, 2.1]; p = 0.004), intrusion (OR = 1.6 [1.1, 2.1]; p = 0.006), and hyper-arousal (OR = 1.3 [1.0, 1.8]; p = 0.088). We concluded that persons with CML during the SARS-CoV-2 pandemic have worse mental health including depression, anxiety, and distress symptoms. Decreasing or stopping monitoring or dose resulted in adverse mental health consequences. There are many reports of increased prevalence and severity of mental health problems including those of depression, anxiety, and distress during the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic in the general population, medical health care workers (1) (2) (3) (4) (5) (6) (7) (8) (9) , and persons with chronic diseases (10, 11) . Several studies reported that cancer patients experienced mental health problems or worse healthrelated quality of life (HRQoL) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) , which were associated with delay in cancer care or reduced therapy intensity. However, the impact of the pandemic on the mental health of persons with leukemia is rare, and there is none in persons with chronic myeloid leukemia (CML). The mental health of persons with CML is of concern because they require long-term tyrosine kinase-inhibitor (TKI) therapy response monitoring and TKI dose adjustments (22) . Data from before the pandemic indicate that persons with CML experience more severe depression and/or anxiety to daily life challenges compared with controls (23) (24) (25) (26) (27) . Several studies reported prevalence and/or severity of SARS-CoV-2-infection and of coronavirus infectious disease 2019 in persons with CML (28-31) compared with controls. There are no data on the mental health of persons with CML during the SARS-CoV-2 pandemic. Therefore, we performed a crosssectional survey to explore the prevalence of depression, anxiety, and distress symptoms in 3, 197 subjects with CML during the pandemic. Results were compared with concurrent controls, which were non-cancer persons and immediate family members of persons with cancer including CML. We were especially interested in the effects on mental health of adjustments in the frequency of monitoring response to TKI therapy and/or dose. From April 28 to May 12, 2020, a cross-sectional online survey was done using the WeChat-based survey program Wenjuanwang. Persons diagnosed with CML, non-cancer persons, and immediate family members of persons with cancer including CML as controls (≥ 16 years) in China were invited to participate in the survey. Persons diagnosed with CML after February 2020 and those with COVID-19 were excluded. The studies involving human participants were reviewed and approved by the Ethics Committee of Peking University People's Hospital who waived the requirement for informed consent because of the outbreak of SARS-CoV-2. The questionnaire consisted of five dimensions (Supplementary Contents 1, 2) . The first dimension included a brief introduction of the survey and a question about whether having filled out the questionnaire before. The second dimension included 10 questions assessing demographics. The third included 15 questions about CML-related data such as diagnosis, therapy, and response. The fourth included 11 questions about behavior and experience at the peak of the COVID-19 pandemic in China, the end of January to end of March (32) (33) (34) . The fifth included three self-reported validated measurement tools in Chinese version including the 9-item Patient Health Questionnaire (PHQ-9), the 7-item Generalized Anxiety Disorder (GAD-7), and the 22-item Impact of Event Scale-Revised (IES-R) to assess the prevalence and severity of depression, anxiety, and distress during the end of January to April. The questionnaire was the same for age and subjects with CML except for CML-related questions (the third dimension). Comorbidities were defined as coexisting diseases except CML and COVID-19. The PHQ-9 (range, 0-27) was used to assess depression symptoms with the total scores categorized as follows: controls (0-4), mild (5-9), moderate (10) (11) (12) (13) (14) , and severe (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (35) . The GAD-7 (range, 0-21) was used to assess anxiety symptoms with the total scores categorized as follows: controls (0-4), mild (5-9), moderate (10) (11) (12) (13) (14) , and severe (15) (16) (17) (18) (19) (20) (21) (36) . The IES-R (range, 0-88) was used to assess subjective distress (excessive panic and anxiety) caused by traumatic events including traumarelated distressing memories and persistent negative emotions resulting from the pandemic, which is composed of three subscales to measure the avoidance, intrusion, and hyper-arousal. The total IES-R score was categorized as follows: subclinical (0-8), mild (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) , moderate (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) , and severe (44-88) (37) . Respondents who had the scores greater than the cutoff threshold of 10 in PHQ-9, 10 in GAD-7, and 26 in IES-R indicate moderate to severe depression, anxiety, and distress, respectively, and IES-R score ≥ 26 is associated with post-traumatic stress disorder (PTSD) symptoms (35, 38, 39) . Descriptive analysis results were presented as median (range) or number (percent). Categorical variables were compared with the chi-square test and continuous variables with the Mann-Whitney test. The k-means clustering method was used to cluster the three subscales of distress including avoidance, intrusion, and hyper-arousal symptoms derived from the IES-R. To identify the variables associated with the poor mental health in responses with CML and controls, covariates including age, sex, education level, marital status, household registration (rural vs. urban), comorbidity(ies), residence in Hubei province or elsewhere, cohabitation, behavior and experience (such as following pandemic information frequently, sharing feelings actively), and having an acute respiratory symptom during the pandemic were used to analyze the association with the moderate to severe depression, anxiety, and distress, as well as the presence of avoidance, intrusion, and hyper-arousal by the k-means clustering analysis. To identify the covariates associated with the poor mental health in persons with CML, CML-related data including disease phase, CML and TKI therapy duration, TKI used, TKI therapy line, treatment response, interruption or delay in disease monitoring, and interruption or dose reduction of TKI therapy were used to analyze. Covariates with p < 0.2 in univariate analysis were included in the multivariate binary logistic regression analyses. P < 0.05 was considered statistically significant. Analyses were conducted with SPSS Version 22.0 software. From April 28 to May 12, 2020, data of 3,581 respondents with CML and 7,556 controls from 32 provinces and municipalities across China were collected. Questionnaires from subjects < 16 years (n = 121), duplicates (n = 513), subjects with CML diagnosed after February 2020 (n = 42), and persons with COVID-19 (n = 8) were excluded. The updated dataset consisted of 3,197 respondents with CML and 7,256 controls. Respondent covariates are shown in Table 1 restriction (n = 768; 24%), clinic or laboratory closure (n = 279; 9%), or other reasons (n = 29; 1%). Two hundred three (6%) respondents had TKI dose reduction or discontinuation because of the travel restriction (n = 147; 5%), fear of SARS-CoV-2 infection in the hospital or during travel (n = 108; 3%), clinic closure (n = 41; 1%), no access to TKI from patient assistance program (n = 39; 1%) or clinical trial (n = 10; 0.3%), or other reasons (n = 32; 1%). Compared with controls, more respondents with CML were male (p < 0.001), older (p < 0.001), and married (p < 0.001), had lower education level (p < 0.001), and had a comorbidity(ies) (p < 0.001). Proportions of respondents from Hubei province were comparable (p = 0.25). During the SARS-CoV-2 pandemic, more respondents with CML were rural residents (p < 0.001) and cohabited with their family members or friends (p < 0.001). Fewer respondents with CML followed pandemic information frequently (p < 0.001), shared feelings actively (p < 0.001), reported being exposed to someone with COVID-19 (p < 0.001), or had a family member with an acute respiratory symptom (p = 0.001). In contrast, more reported that they had an acute respiratory symptom (p < 0.001), fewer suspected that they were infected with SARS-CoV-2 (p = 0.049), more went to a hospital (p < 0.001), and had a lung computed tomography (CT) scan (p < 0.001). Data from respondents with CML indicated a higher prevalence of depression (PHQ-9 score ≥ 5, 33%, 95% confidence interval [CI], [ [19, 21%] , p < 0.001) by k-means clustering analyses (Figure 1, Table 2 ; p < 0.001). In addition, having comorbidity(ies), following the pandemic information frequently, and having an acute respiratory symptom were significantly associated with moderate to severe depression, anxiety, distress, avoidance, intrusion, and hyper-arousal. Female sex, increasing age, unmarried, divorced, or widowed marital status, and living in Hubei province were significantly associated with ≥1 symptom of mental health described above; however, for those who were sharing feelings actively, there was no or mild depression ( Table 3) . We collected data from subjects with CML on the disease phase at diagnosis, with the interval from diagnosis to starting TKI therapy, CML duration, TKI therapy duration, current therapy, the number of TKI therapy lines given, response (MMR vs.